Oct 14
2026
Phanes Therapeutics announces first patient with colorectal cancer (CRC) dosed in clinical study of spevatamig
SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery...
Read More
Oct 13
2026
Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026
SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery...
Read More
Sep 16
2026
Phanes Therapeutics announces US patent granted to its proprietary bispecific antibody technology platform PACbody®
SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery...
Read More
Aug 14
2026
Phanes Therapeutics receives FDA Fast Track designation for spevatamig in advanced and metastatic biliary tract carcinoma
Spevatamig is Phanes' anti-CLDN18.2/CD47 bispecific antibody that functions as an innate immunity enhancer (I2E), an emerging class of immuno-oncology (IO)...
Read More
Jul 21
2026
Phanes Therapeutics announces expansion of clinical trial collaboration and supply agreement with Merck to evaluate spevatamig in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for treatment of biliary tract cancer
Spevatamig is Phanes' anti-CLDN18.2/CD47 bispecific antibody that functions as an innate immunity enhancer (I₂E), an emerging class of immuno-oncology (IO)...
Read More
Jun 22
2026
Phanes Therapeutics announces completion of enrollment in Phase 2 clinical trial of spevatamig in combination with chemotherapy for the frontline treatment of metastatic pancreatic ductal adenocarcinoma
Two dose levels of spevatamig in combination with standard of care chemotherapy are being evaluated as frontline (1L) treatment for metastatic...
Read More
May 28
2026
Phanes Therapeutics announces updated Phase 2 clinical trial results of spevatamig (PT886) in combination with chemotherapy in frontline treatment of metastatic PDAC at the 2026 ASCO annual meeting
SAN DIEGO, May 28, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development...
Read More
Apr 22
2026
Phanes Therapeutics to present updated Phase 2 clinical trial results of spevatamig (PT886) in combination with chemotherapy in frontline treatment of metastatic PDAC at the 2026 ASCO annual meeting
SAN DIEGO, April 22, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development...
Read More
Apr 7
2026
Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer
SAN DIEGO, April 7, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development...
Read More
Mar 18
2026
Phanes Therapeutics to present three clinical posters at AACR 2026
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
